Simeonidis Harry 4

What Happened

• Harry Simeonidis, CEO of Intelligent Bio Solutions, received two equity awards on March 18, 2026 totaling 30,500 restricted shares of common stock. The grants were reported on a Form 4 filed March 20, 2026. Both awards were granted at $0.00 per share (i.e., no purchase price paid) and are subject to forfeiture until vested.
• The awards break down to 9,150 restricted shares that vest based on time (48 months) and 21,350 restricted shares that vest subject to joint performance-based and time-based conditions.

Key Details

• Transaction date: March 18, 2026; Form 4 filed March 20, 2026 (filed within the typical two-business-day reporting window).
• Price: $0.00 per share (grant/award).
• Shares granted: 9,150 (time-based, 48-month vesting) + 21,350 (performance + time-based vesting) = 30,500 total.
• Post-split reporting: All amounts are presented on a post-1-for-10 reverse split basis effected December 15, 2025 (per filing footnote).
• Forfeiture/vesting: Awards are subject to forfeiture until vesting; the 21,350-share award includes performance conditions.
• Shares owned after the transaction: Not specified in the provided filing excerpt.

Context

• These are restricted stock awards (code A on Form 4) rather than purchases or sales; awards at $0 simply reflect stock grants, not market purchases. Such grants are common for executive compensation and do not, by themselves, indicate immediate selling or buying activity in the open market.